title: Ibandronate in the treatment of prostate cancer associated painful osseous metastases.
abstract: The aim of our study was to assess the clinical efficacy and toxicity of ibandronate in the management of symptomatic skeletal metastases due to prostate cancer (PCA). Twenty-five patients with painful osseous metastases due to hormone refractory PCA (HRPCA) were treated with 6 mg ibandronate every 4 weeks in an open prospective non-randomized clinical study. Primary study endpoint was pain reduction documented by the use of a 10-point visual analog scale. Palliative response with significant reduction in pain score from 6.5 (5-10) to 2.0 [(0-4), P<0.001] was achieved in 23 (92%) patients; nine patients (39%) were completely pain free. Bisphosphonate treatment of painful osseous metastases due to HRPCA resulted in a significant pain reduction and a significant decrease of daily consumption of analgesics in 92% of the patients. Both characteristics are paralleled by an increase in Karnofsky index mainly due to better mobility. Bisphosphonates should have a definite role in the palliative management of symptomatic HRPCA.
authors.affiliation: Department of Urology, Philipps - University Marburg, Baldingerstrasse, Marburg, Germany. heidenre@post.med.uni-marburg.de
authors.forename: A
authors.initials: A
authors.lastname: Heidenreich
authors.forename: A
authors.initials: A
authors.lastname: Elert
authors.forename: R
authors.initials: R
authors.lastname: Hofmann
mesh_terms: D000368:Aged; D001859:Bone Neoplasms / Q000503:physiopathology / Q000556:secondary*; D004164:Diphosphonates / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D000077557:Ibandronic Acid; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000188:drug therapy*; D011446:Prospective Studies; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D004164:Diphosphonates; D000077557:Ibandronic Acid